Back to today’s briefing

Story perspectives

FDA Unveils Fast-Track Pathway for Gene Editing Therapies

11/13/2025

31 7

Summary

Story summary

The FDA has introduced the plausible mechanism pathway to expedite approvals of bespoke gene editing therapies.
FDA officials Martin Makary and Vinay Prasad described the framework in the New England Journal of Medicine.
The framework focuses on assessing underlying science over extensive efficacy studies.
It aims for quicker market access, illustrated by baby KJ's CRISPR treatment.

1 of 1

Story summary

The FDA has introduced the plausible mechanism pathway to expedite approvals of bespoke gene editing therapies.
FDA officials Martin Makary and Vinay Prasad described the framework in the New England Journal of Medicine.
The framework focuses on assessing underlying science over extensive efficacy studies.
It aims for quicker market access, illustrated by baby KJ's CRISPR treatment.